200 related articles for article (PubMed ID: 32887573)
1. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer.
Coebergh van den Braak RRJ; Ten Hoorn S; Sieuwerts AM; Tuynman JB; Smid M; Wilting SM; Martens JWM; Punt CJA; Foekens JA; Medema JP; IJzermans JNM; Vermeulen L
BMC Cancer; 2020 Sep; 20(1):850. PubMed ID: 32887573
[TBL] [Abstract][Full Text] [Related]
2. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
3. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
4. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
5. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
6. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
7. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
8. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.
Alderdice M; Richman SD; Gollins S; Stewart JP; Hurt C; Adams R; McCorry AM; Roddy AC; Vimalachandran D; Isella C; Medico E; Maughan T; McArt DG; Lawler M; Dunne PD
J Pathol; 2018 May; 245(1):19-28. PubMed ID: 29412457
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
Kwon Y; Park M; Jang M; Yun S; Kim WK; Kim S; Paik S; Lee HJ; Hong S; Kim TI; Min B; Kim H
Oncotarget; 2017 Jun; 8(24):39367-39381. PubMed ID: 28455965
[TBL] [Abstract][Full Text] [Related]
12. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
13. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B.
Daemen A; Udyavar AR; Sandmann T; Li C; Bosch LJW; O'Gorman W; Li Y; Au-Yeung A; Takahashi C; Kabbarah O; Bourgon R; Hegde P; Bais C; Das Thakur M
PLoS One; 2021; 16(12):e0262198. PubMed ID: 34972191
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
16. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.
Lee MS; Menter DG; Kopetz S
J Natl Compr Canc Netw; 2017 Mar; 15(3):411-419. PubMed ID: 28275039
[TBL] [Abstract][Full Text] [Related]
17. Molecular subtyping improves prognostication of Stage 2 colorectal cancer.
Purcell RV; Schmeier S; Lau YC; Pearson JF; Frizelle FA
BMC Cancer; 2019 Nov; 19(1):1155. PubMed ID: 31775679
[TBL] [Abstract][Full Text] [Related]
18. Cofilin-1, LIMK1 and SSH1 are differentially expressed in locally advanced colorectal cancer and according to consensus molecular subtypes.
Sousa-Squiavinato ACM; Vasconcelos RI; Gehren AS; Fernandes PV; de Oliveira IM; Boroni M; Morgado-Díaz JA
Cancer Cell Int; 2021 Jan; 21(1):69. PubMed ID: 33482809
[TBL] [Abstract][Full Text] [Related]
19. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
[TBL] [Abstract][Full Text] [Related]
20. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.
Perez-Villamil B; Romera-Lopez A; Hernandez-Prieto S; Lopez-Campos G; Calles A; Lopez-Asenjo JA; Sanz-Ortega J; Fernandez-Perez C; Sastre J; Alfonso R; Caldes T; Martin-Sanchez F; Diaz-Rubio E
BMC Cancer; 2012 Jun; 12():260. PubMed ID: 22712570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
